Generic User Fee Transition A Little Bumpy For Contract Manufacturers
Executive Summary
Problems with self-identification process caused by timing of legislative renewal may have affected figures used by US FDA to calculate FY 2018 GDUFA fees.
You may also be interested in...
Inside The ANDA Parking Lot
A firm will take ownership of US ANDAs from manufacturers unwilling to pay program fees or withdraw the approved generic drug application; is it a novel concept allowing future marketing options or simply fee avoidance?
Inside The ANDA Parking Lot
A firm will take ownership of US ANDAs from manufacturers unwilling to pay program fees or withdraw the approved generic drug application; is it a novel concept allowing future marketing options or simply fee avoidance?
US FDA Changes Data Source For GDUFA II Facility Fee Setting
Agency primarily uses application data instead of facility self-identification lists to determine FY 2018 generic drug user fees.